Compare ARVN & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | RNST |
|---|---|---|
| Founded | 2015 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 3.6B |
| IPO Year | 2018 | 1997 |
| Metric | ARVN | RNST |
|---|---|---|
| Price | $7.43 | $39.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | $13.93 | ★ $48.14 |
| AVG Volume (30 Days) | ★ 703.7K | 522.0K |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 2.47% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | 1.70 | ★ 1.88 |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $12.76 | $12.18 |
| Revenue Next Year | N/A | $3.21 |
| P/E Ratio | ★ $4.40 | $21.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.97 | $33.04 |
| 52 Week High | $14.22 | $44.54 |
| Indicator | ARVN | RNST |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 27.31 |
| Support Level | N/A | $35.04 |
| Resistance Level | $8.52 | $40.84 |
| Average True Range (ATR) | 0.31 | 0.66 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 32.09 | 0.00 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.